Cargando…

What More Can Be Delivered to Future Patients with Coronary Syndromes?

Detalles Bibliográficos
Autores principales:	Tanaka, Atsushi, Node, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570615/ https://www.ncbi.nlm.nih.gov/pubmed/36233571 http://dx.doi.org/10.3390/jcm11195704

Ejemplares similares

Polycystic ovary syndrome: What more can be done for patients?
por: The Lancet Regional Health – Europe
Publicado: (2022)

Collective Knowledge Used to Unveil Cardiovascular Injury Emerged during COVID-19
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Prediction of Stroke After Cardiac Catheterization: No Reason, No Stroke
por: Tanaka, Atsushi, et al.
Publicado: (2018)

So‐far overlooked HFpEF patients with normal natriuretic peptide level need more evidence
por: Tanaka, Atsushi, et al.
Publicado: (2022)

The Emerging and Promising Role of Care for Cardiometabolic Syndrome in Prostate Cancer
por: Tanaka, Atsushi, et al.
Publicado: (2019)

Phenotyping acute exacerbation of COPD: what more can we do for hospitalised patients?
por: Cen, Lai-Jian, et al.
Publicado: (2021)

Perioperative Care in Patients with Chronic Liver Disease: What Can We Do More?
por: Droc, Gabriela, et al.
Publicado: (2023)

More Evidence on the Effects of Deworming: What Lessons Can We Learn?
por: Croke, Kevin, et al.
Publicado: (2017)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome
por: Tanaka, Atsushi, et al.
Publicado: (2017)

HEDIS, Beta-Blockers, and What More Can Be Done to Improve Secondary Prevention in ACS
por: Curtiss, Frederic R.
Publicado: (2008)

Time-restricted feeding: what we have done and what more we can do?
por: Sun, Yuning, et al.
Publicado: (2023)

The Future of Pathology: What can we Learn from the COVID-19 Pandemic?
por: Williams, Bethany J, et al.
Publicado: (2020)

Respect for Evidence: Can Science Education Deliver It?
por: Erduran, Sibel
Publicado: (2021)

The ‘What, Why, Where and How’ of Delivering a Drug
por: Mukherjee, Kusumika
Publicado: (2020)

More is not always better—what can be learned from the D-CARE trial
por: Pfeiler, Georg, et al.
Publicado: (2020)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials
por: Tanaka, Atsushi, et al.
Publicado: (2019)

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
por: Tanaka, Atsushi, et al.
Publicado: (2020)

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Crosstalk between the liver and heart: revisited for prevention and treatment
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
por: Tanaka, Atsushi, et al.
Publicado: (2021)

In‐hospital therapy for worsening heart failure: black box or sweet spot?
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Zooming into Cellular and Molecular Heterogeneity of Pulmonary Hypertension. What More Single-Cell Omics Can Offer
por: Chelladurai, Prakash, et al.
Publicado: (2021)

More Than Just Access: Delivering on a Network-Enabled Literature
por: Neylon, Cameron
Publicado: (2012)

The Future of Ageing: not more of the same
por: Sikora, Ewa, et al.
Publicado: (2017)

Takotsubo Syndrome After Additional Right Ventricular Lead Insertion in a Pacemaker User
por: Yoshioka, Goro, et al.
Publicado: (2022)

Rheumatoid Arthritis and Vascular Failure - Rheumatoid Arthritis Is a Risk Factor for Cardiovascular Disease-
por: Oyama, Jun-ichi, et al.
Publicado: (2019)

The future is not what it used to be
por: Stanistreet, Paul
Publicado: (2023)

Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report
por: Matsumura, Daisuke, et al.
Publicado: (2016)

Radiologically isolated syndrome in children: Can we predict future events?
por: Yeh, E. Ann
Publicado: (2017)

Can Less be More in Intensive Care?
por: Kapadia, Farhad N., et al.
Publicado: (2017)

Can We Do More for ISIM?
por: Asscher, A. W., et al.
Publicado: (1979)

Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future?
por: Cagnazzo, Celeste, et al.
Publicado: (2020)

Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells
por: Tanaka, Atsushi, et al.
Publicado: (2015)

What is the future for surgical oncology?
por: Thompson, A M
Publicado: (2011)

Mental Nurses: What Is Their Future?
Publicado: (1961)

What does the future hold?
por: de Campos, Fernando Peixoto Ferraz
Publicado: (2012)

What is the future of suicide genetics?
por: Mirza, Salahudeen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rka5vspv2nv468k5dtglv0jhss